Clinical Report: Addressing Tamoxifen-Associated Weight Gain: Lifestyle and Pharmacotherapy Options

Overview

Tamoxifen therapy for hormone receptor-positive breast cancer is linked to significant weight gain in a substantial proportion of women. This report discusses the prevalence, mechanisms, and management strategies for tamoxifen-associated weight gain.

Background

Breast cancer remains a leading cause of cancer-related mortality among women in the U.S., with hormone receptor-positive cases constituting the majority. While tamoxifen is effective in reducing recurrence and mortality, its association with weight gain poses additional health risks for survivors. Understanding and managing this weight gain is crucial for improving long-term outcomes in breast cancer survivors.

Data Highlights

Key Findings

• 39% to 61% of women on tamoxifen experience weight gain, influenced by menopausal status and treatment duration.
• Weight gain is more pronounced in women with lower initial fat mass and those with prior chemotherapy.
• Tamoxifen may disrupt appetite regulation and lipid metabolism, contributing to weight gain.
• Excess adiposity in breast cancer survivors is linked to higher recurrence and mortality risks.
• Current guidelines emphasize the importance of weight management in cancer survivorship care.

Clinical Implications

Healthcare providers should monitor weight changes in patients undergoing tamoxifen therapy and consider lifestyle interventions or pharmacotherapy for weight management. Comprehensive assessments, including body composition analysis, are recommended to tailor individual management strategies.

Conclusion

Addressing tamoxifen-associated weight gain is essential for optimizing the health and survivorship of women with hormone receptor-positive breast cancer. Effective management strategies can mitigate the associated risks and improve overall outcomes.

References

1. American Cancer Society, 2026 -- Breast Cancer Facts & Figures
2. Burstein et al., 2019 -- Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer
3. Bekes & Huober, 2023 -- Long-term Outcomes of Tamoxifen Therapy
4. Ligibel et al., 2022 -- Obesity and Breast Cancer Outcomes
5. The ASCO Post — Women at Increased Risk for Breast Cancer Should Be Offered Medications to Reduce Risk, Draft Recommendations Advise
6. The ASCO Post — Anticipate Difficulties by Patients in Adhering to Tamoxifen Therapy
7. The New Gastroenterologist — Strategies for Managing Weight in Gastroenterology Practice
8. The ASCO Post — Gauging the Impact of Weight Loss Intervention on Breast Cancer Outcomes
9. NCCN Guidelines® Insights - Survivorship, Version 2.2025
10. BWEL Weight-Loss Trial Reports Success for Patients With Breast Cancer at 1-Year Mark
11. WHO issues global guideline on the use of GLP-1 medicines in treating obesity